Step 1 topics → Immunology → Type II Hypersensitivity (Antibody vs Fixed Antigen)

Type II Hypersensitivity (Antibody vs Fixed Antigen)

USMLE Step 1 trap: Confuses Goodpasture (linear IF, fixed antigen, Type II) with PSGN (granular IF, immune complex, Type III). Goodpasture syndrome is Type II hypersensitivity with anti-GBM antibodies binding fixed collagen IV antigen, producing linear IF staining; PSGN is Type III with immune complex deposition producing granular (lumpy-bumpy) IF staining.

Type II hypersensitivity is the one where antibodies (IgG or IgM) target antigens that are fixed to cell surfaces or tissue — not floating free in serum, not in an immune complex — and USMLE Step 1 tests it constantly because it underlies a dense cluster of high-yield diseases. That distinction between fixed and floating antigen is the whole ballgame. The exam tests this concept constantly because it underlies a dense cluster of high-yield diseases: Goodpasture syndrome, Graves' disease, myasthenia gravis, AIHA, ITP, and hyperacute transplant rejection. USMLE Step 1 will rarely ask you to just name the hypersensitivity type — instead, it gives you a clinical vignette and makes you reason from mechanism to presentation or from lab finding to diagnosis.

The trickiest part is that Type II isn't one mechanism — it's three (complement lysis, ADCC, opsonization), and the receptor-targeting diseases split into stimulating vs. blocking, which produce opposite clinical pictures. Most students collapse all of this into 'antibody attacks cell, complement kills it,' and that mental model will get you burned on questions about Graves' disease or myasthenia. The other classic trap is Goodpasture vs. post-streptococcal glomerulonephritis — both hit the kidney, both involve antibody, but they're different hypersensitivity types with different immunofluorescence patterns, and the exam exploits that confusion directly.

On USMLE Step 1, you'll see this tested through mechanism questions ('why does this patient have hemolytic anemia'), disease identification from target antigen, and passage-based differentials where immunofluorescence data or clinical features force you to distinguish Type II from Type III. Build your framework around the fixed-antigen concept and work outward from there.

From real student decks
81%have cards covering this topic
57%have mature cards

Common misconceptions

Common mistake
Wrong: Goodpasture syndrome is caused by immune complex deposition like post-streptococcal glomerulonephritis.
Right: Goodpasture syndrome is Type II hypersensitivity with anti-GBM antibodies binding fixed collagen IV antigen, producing linear IF staining; PSGN is Type III with immune complex deposition producing granular (lumpy-bumpy) IF staining.
The key difference is where the antibody binds. In Goodpasture syndrome, the antibody recognizes collagen IV, which is a permanent structural component of the glomerular basement membrane — it's already there, and the antibody homes in on it directly. This produces smooth, continuous linear staining on immunofluorescence. In PSGN, antibodies form complexes with streptococcal antigens in the circulation, and those preformed complexes deposit in the glomerulus — the antigen isn't native to the kidney. This produces irregular, granular (lumpy-bumpy) staining. Linear IF = Type II, fixed antigen. Granular IF = Type III, immune complex. The exam gives you the IF result and expects you to work backward to mechanism.
Common mistake
Wrong: All Type II receptor-targeting autoantibodies block receptor function, causing disease by receptor loss.
Right: Some Type II autoantibodies stimulate receptors (e.g., TSI in Graves' disease activates TSH-R causing hyperthyroidism), while others block them (e.g., anti-AChR in myasthenia gravis causes weakness); the clinical effect depends on antibody action.
It's wrong to assume all autoantibodies that hit receptors block them — that's only half the picture. An antibody binding a receptor can either block the ligand's access (antagonist effect, as in myasthenia gravis where anti-AChR prevents acetylcholine from binding, causing weakness) or mimic the ligand and activate the receptor (agonist effect, as in Graves' disease where thyroid-stimulating immunoglobulins continuously activate TSH-R, causing hyperthyroidism). The clinical presentation flips completely depending on which action the antibody has. When you see a receptor-targeting autoimmune disease on USMLE Step 1, ask yourself: is the antibody turning the receptor on or off?
Common mistake
Wrong: Type II hypersensitivity is mediated solely by complement activation.
Right: Type II hypersensitivity uses three effector routes: complement-mediated lysis, antibody-dependent cellular cytotoxicity (ADCC) via NK cells/macrophages, and opsonization for phagocytosis.
Complement is just one of three weapons in the Type II arsenal — anchoring your understanding there will cost you points. The full picture: (1) IgG/IgM activates complement via the classical pathway, leading to MAC-mediated lysis; (2) antibody-coated cells get recognized by NK cells and macrophages via Fc receptors, triggering ADCC — the cell is killed without complement; (3) opsonization by IgG and C3b marks cells for phagocytosis by macrophages and neutrophils. Each mechanism can dominate in different Type II diseases — ADCC is particularly relevant for explaining NK-cell involvement, and opsonization explains why ITP platelets are cleared in the spleen. Know all three.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know all three effector routes antibodies use to destroy fixed-antigen targets: complement-mediated lysis (MAC), ADCC via NK cells and macrophages binding Fc receptors, and opsonization leading to phagocytosis — the exam expects you to name and apply all three, not just complement.
  2. Identify the target antigen for each classic Type II disease: anti-GBM collagen IV in Goodpasture, anti-RBC antigens in AIHA, anti-platelet antigens in ITP, anti-AChR in myasthenia gravis, anti-TSH-R in Graves' disease, anti-desmoglein in pemphigus vulgaris — vignettes often reveal the antigen indirectly through clinical features.
  3. Distinguish receptor-stimulating autoantibodies (Graves' — TSI activates TSH-R → hyperthyroidism) from receptor-blocking autoantibodies (myasthenia gravis — anti-AChR blocks → weakness) — the clinical effects are opposite and the exam will test whether you know which is which.
  4. Differentiate Goodpasture syndrome (Type II, anti-GBM antibody binding fixed collagen IV, linear immunofluorescence) from post-streptococcal glomerulonephritis (Type III, immune complex deposition, granular/lumpy-bumpy immunofluorescence) using both mechanism and IF pattern.

Can you avoid these mistakes?

A patient with hemoptysis and hematuria has immunofluorescence showing linear staining along the glomerular basement membrane. What is the mechanism of renal injury, what antibody is responsible, and how does this differ from the IF pattern you'd see in post-streptococcal glomerulonephritis?
A 35-year-old woman is found to have low TSH, high T3/T4, a diffusely enlarged thyroid, and eye findings consistent with Graves' disease. Her autoantibodies target the TSH receptor. Explain why this is Type II hypersensitivity and why the disease causes hyperthyroidism rather than hypothyroidism — what does the antibody do to the receptor?
A patient with warm autoimmune hemolytic anemia has IgG antibodies coating her red blood cells. Her spleen is intact. Without naming complement lysis as an option, identify two other mechanisms by which IgG bound to a cell surface can mediate its destruction — and for each, name the key cell type or effector pathway involved.
A patient on quinine develops acute hemolytic anemia. The drug acts as a hapten on red blood cell surfaces, triggering an IgG response against drug-coated RBCs. Which hypersensitivity type is this, and through which effector mechanism(s) are the RBCs most likely being destroyed?

Related topics

Immunoglobulin Structure and Isotypes Thymus and T Cell Maturation Spleen Architecture and Function Lymph Node and MALT Architecture Innate Immune Cells Overview

See how your Anki deck covers this topic.

Upload your deck for a free audit →